Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
  1. Home
  3. Analysis Of Treatment-free Survival Of Patients With Advanced Melanoma Receiving Nivolumab As Monotherapy Or In Combination With Relatlimab In Relativity-047.
  1. Home
  3. Analysis Of Treatment-free Survival Of Patients With Advanced Melanoma Receiving Nivolumab As Monotherapy Or In Combination With Relatlimab In Relativity-047.

Related Experiment Video

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.2K

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in

Meredith M Regan1, Paolo A Ascierto2, Evan J Lipson3

  • 1Dana-Farber Cancer Institute, Boston, Massachusetts, USA mregan@jimmy.harvard.edu.

Journal for Immunotherapy of Cancer
|September 12, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Immune Checkpoint InhibitorImmunotherapySkin Cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.4K

Related Experiment Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.4K

Nivolumab plus relatlimab demonstrated a significant treatment-free survival (TFS) benefit compared to nivolumab alone in advanced melanoma patients over 48 months. This indicates more time without therapy and fewer treatment-related adverse events for patients receiving the combination.

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Research

Background:

  • Treatment-free survival (TFS) is a key endpoint in advanced melanoma, measuring time without systemic anticancer therapy.
  • Previous studies evaluated TFS with nivolumab plus ipilimumab.
  • This analysis compares TFS for nivolumab plus relatlimab versus nivolumab monotherapy.

Purpose of the Study:

  • To compare treatment-free survival (TFS) between nivolumab plus relatlimab and nivolumab monotherapy in advanced melanoma.
  • To assess TFS partitioned by treatment-related adverse events (TRAEs).
  • To analyze TFS across subgroups based on BRAF mutational status and PD-L1 expression.

Main Methods:

  • Utilized data from 714 patients in the RELATIVITY-047 trial (NCT03470922).
  • Defined TFS as time to protocol therapy cessation or subsequent therapy/death.
  • Calculated differences using bootstrapped 95% CIs and analyzed subgroups.

    • Main Results:

    • At 48 months, nivolumab plus relatlimab showed a mean TFS 2.9 months longer than nivolumab (9.7 vs 6.8 months).
    • Patients on nivolumab plus relatlimab spent more time free of grade ≥3 TRAEs (9.1 vs 6.5 months).
    • Consistent TFS benefits were observed across BRAF mutant/wild-type and PD-L1 expression subgroups.

    Conclusions:

    • Nivolumab plus relatlimab provides a TFS benefit over nivolumab alone in advanced melanoma up to 48 months.
    • Further research is needed to directly compare TFS with nivolumab plus ipilimumab.
    • TFS is a valuable endpoint supporting traditional measures in advanced melanoma treatment.